Stock Details
AZN is AstraZeneca PLC's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 68.13$. Average daily volumn in 3 months 5.03M. Market cap 204.73B



Stock symbol : AZN. Exchange : NasdaqGS. Currency : USD
Lastest price : 65.53$. Total volume : 3.18M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

AstraZeneca PLC (AZN)
Last Price
65.53$
Change
-0.46
Volume
3.18M

Previous Close65.99
Open65.40
Day Range65.19-65.78
Bid65.56 x 1.8k
Ask65.52 x 1.1k
Volume3.18M
Average Volume5.03M
Market Cap204.73B
Beta0.23
52 Week Range52.65-72.12
Trailing P/E102.39
Foward P/E17.90
Dividend (Yield %)2.21%
Ex-Dividend Date2022-08-11



Financial Details


According to AstraZeneca PLC's financial reports the company's revenue in 2021 were 37.42B an increase( +42.31%) over the years 2020 revenue that were of 26.62B. In 2021 the company's total earnings were 112M while total earnings in 2020 were 3.2B(-96.27%).


Loading ...



Organization

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolis... m diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Cap:
204.73B
Revenue:
37.42B
Total Assets:
105.36B
Total Cash:
6.33B


News about "AstraZeneca PLC"

astrazeneca-plc-adr-outperforms-market-on-strong-trading-day-image

AstraZeneca PLC ADR outperforms market on strong trading day

Source from : MarketWatch - 3 days ago

The AstraZeneca PLC ADR inched 0.53% higher to $66.63 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the ...See details»


AstraZeneca PLC (AZN) Getting Ready To Launch, Waiting For The Long Term Buyers

Source from : stocksregister - 2 days ago

AstraZeneca PLC (NASDAQ:AZN) at last check was buoying at $65.83 on Thursday, January 26, with a fall of -1.19% from its closing price on previous day. Taking a look at stock we notice that its last ...See details»


is-astrazeneca-plc-azn-a-keeper-image

Is AstraZeneca PLC (AZN) a Keeper?

Source from : newsheater - 2 years ago

AstraZeneca PLC (NASDAQ:AZN) went down by -0.96% from its latest closing price compared to the recent 1-year high of $72.12. The companyโ€™s stock price has collected -6.38% of loss in the last five ...See details»


How to Buy AstraZeneca PLC (AZN) Stock

Source from : Benzinga.com - 1 month ago

International biopharmaceutical company AstraZeneca PLC (NASDAQ: AZN) has recently released its own candidate for COVID-19 strains, with trials showing up to 90% efficacy rates. If youโ€™re a new ...See details»


AstraZeneca PLC: Reaffirming BUY and $75 target

Source from : YAHOO!Finance - 5 days ago

Find the latest Astrazeneca PLC (AZN) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»


AstraZeneca rises Wednesday, outperforms market

Source from : MarketWatch - 3 days ago

AstraZeneca PLC AZN shares inched up 0.93% to ยฃ108.10 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index UKX falling 0.16% to 7,744.87.See details»


AstraZeneca PLC (LON:AZN) is a favorite amongst institutional investors who own 88%

Source from : Yahoo - 1 month ago

A look at the shareholders of AstraZeneca PLC (LON:AZN) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 88% ownership. In other ...See details»


AstraZeneca To Buy CinCor Pharma In Up To $1.8 Bln Deal - Quick Facts

Source from : Business Insider - 20 days ago

A stylized camera. The word "Insider". (RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) Monday said it has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CINC), a ...See details»


astrazeneca plc

Source from : Fox Business - 6 days ago

AstraZeneca recorded a big jump in revenue on Thursday as it begins to take a profit from its coronavirus vaccine for the first time. Positive clinical trial results for Merck & Co's experimental ...See details»


AstraZeneca to Buy CinCor Pharma for Up to $1.8 Billion

Source from : Bloomberg L.P. - 20 days ago

AstraZeneca Plc agreed to buy US biotech CinCor Pharma Inc. for as much as $1.8 billion to gain a promising new treatment for hypertension and kidney disease. The deal is the first sizable one for ...See details»


AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.

Source from : Stockhouse - 5 days ago

A tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, will be filed today by AstraZeneca PLC (AstraZeneca), AstraZeneca Finance and ...See details»


AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers

Source from : MSN - 1 month ago

AstraZeneca PLC AZN announced that the Japanese Ministry of Health, Labour, and Welfare (โ€œMHLWโ€) has approved its PD-L1 inhibitor Imfinzi (durvalumab) in combination with CTLA-4 antibody ...See details»


AstraZeneca PLC (NASDAQ:AZN) Q3 2022 Earnings Call Transcript

Source from : Yahoo News - 1 month ago

AstraZeneca PLC (NASDAQ:AZN) Q3 2022 Earnings Call Transcript November 10, 2022 AstraZeneca PLC beats earnings expectations. Reported EPS is $0.84, expectations were $0.72. Operator: Good morning to ...See details»


AstraZeneca: Imfinzi Fails To Meet Statistical Significance For Primary Goals In PEARL Trial

Source from : Nasdaq - 1 month ago

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Monday that Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoints of improving overall ...See details»